Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2024-11-14 7:50 pm Sale | 13G | Elevation Oncology Inc. ELEV | Point72 Asset Management L.P. | 500,000 0.800% | -3,540,000 (-87.62%) | View |
2024-11-14 7:05 pm Sale | 13G | Elevation Oncology Inc. ELEV | Logos Global Management LP | 3,500,000 5.900% | -150,000 (-4.11%) | View |
2024-11-14 6:45 pm Sale | 13G | Elevation Oncology Inc. ELEV | ORBIMED ADVISORS LLC | 2,441,275 4.000% | -558,725 (-18.62%) | View |
2024-11-14 4:46 pm Sale | 13G | Elevation Oncology Inc. ELEV | GREAT POINT PARTNERS LLC | 0 0.000% | -3,877,172 (Position Closed) | View |
2024-11-14 4:28 pm Purchase | 13G | Elevation Oncology Inc. ELEV | BIOTECHNOLOGY VALUE FUND L P | 6,230,845 9.990% | 1,779,960 (+39.99%) | View |
2024-11-12 4:26 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Aisling Capital IV LP | 2,913,005 4.920% | 34,709 (+1.21%) | View |
2024-11-12 2:22 pm Unchanged | 13G | Elevation Oncology Inc. ELEV | VANGUARD GROUP INC | 3,071,580 5.190% | 0 (Unchanged) | View |
2024-11-08 11:54 am Purchase | 13G | Elevation Oncology Inc. ELEV | Farallon Capital Partners L.P. | 3,527,482 6.000% | 427,482 (+13.79%) | View |
2024-11-06 2:40 pm Purchase | 13G | Elevation Oncology Inc. ELEV | GOLDMAN SACHS GROUP INC GS | 4,516,577 7.600% | 4,516,577 (New Position) | View |
2024-11-04 11:49 am Purchase | 13G | Elevation Oncology Inc. ELEV | VANGUARD GROUP INC | 3,071,580 5.190% | 3,071,580 (New Position) | View |
2024-10-09 09:01 am Unchanged | 13G | Elevation Oncology Inc. ELEV | Empery Asset Management LP | 4,000,000 4.990% | 0 (Unchanged) | View |
2024-08-15 4:03 pm Purchase | 13G | Elevation Oncology Inc. ELEV | GREAT POINT PARTNERS LLC | 3,877,172 6.560% | 3,877,172 (New Position) | View |
2024-08-08 9:05 pm Sale | 13D | Elevation Oncology Inc. ELEV | venBio Global Strategic Fund III L.P. | 2,031,920 3.400% | -505,851 (-19.93%) | View |
2024-07-15 1:17 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Frazier Life Sciences Public Fund L.P. | 5,993,579 11.000% | 3,035,000 (+102.58%) | View |
2024-04-09 4:26 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Frazier Life Sciences Public Fund L.P. | 2,958,579 6.100% | 2,958,579 (New Position) | View |
2024-02-14 6:42 pm Purchase | 13G | Elevation Oncology Inc. ELEV | ORBIMED ADVISORS LLC | 3,000,000 6.800% | 3,000,000 (New Position) | View |
2024-02-14 4:45 pm Purchase | 13G | Elevation Oncology Inc. ELEV | K2 HealthVentures Equity Trust LLC | 1,784,169 4.000% | 217,705 (+13.90%) | View |
2024-02-14 4:10 pm Purchase | 13G | Elevation Oncology Inc. ELEV | Point72 Asset Management L.P. | 4,040,000 9.400% | 1,918,830 (+90.46%) | View |
2024-02-14 4:00 pm Purchase | 13G | Elevation Oncology Inc. ELEV | TANG CAPITAL PARTNERS LP | 4,300,454 9.990% | 2,944,628 (+217.18%) | View |
2024-02-14 3:02 pm Sale | 13G | Elevation Oncology Inc. ELEV | Cormorant Asset Management LP | 0 0.000% | -1,952,032 (Position Closed) | View |